Daiichi Buys Rights To ArQule Cancer Drug Still In Trials
This article was originally published in PharmAsia News
Daiichi Sankyo and ArQule of the United States have joined forces to develop cancer drugs, beginning with a $75 million investment. The upfront payment by Daiichi is for rights to ArQule's ARQ 197 c-Met inhibitor for liver and other cancers, now in clinical trials in the U.S. The purchase gives Daiichi rights only in China, Taiwan and South Korea, and not in Japan. Trials so far have shown effectiveness for the drug without severe side effects. (Click here for more - a subscription may be required
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.